Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial

Misawa S, Sato Y, Katayama K, et al.

Lancet Neurol · 2016

Grade ARCT
DOI ↗PubMed ↗

Key Findings

  • ●Only RCT in POEMS syndrome (J-POST trial)
  • ●VEGF reduction rate 0.39 with thalidomide vs -0.02 with placebo (p=0.04)
  • ●Sinus bradycardia more frequent with thalidomide (54% vs 0%)

Referenced in (1 disease)

POEMS Syndrome
ID: pmid-27496680DOI: 10.1016/S1474-4422(16)30157-0PMID: 27496680